High
6.4552
Open
6.450
VWAP
6.23
Vol
427.28K
Mkt Cap
241.19M
Low
6.160
Amount
2.66M
EV/EBITDA(TTM)
--
Total Shares
38.27M
EV
-36.69M
EV/OCF(TTM)
--
P/S(TTM)
1.82
Quanterix Corporation is a life sciences company. The Company is engaged in developing ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. Its platforms are based on its digital Simo...Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
28.27M
-11.83%
--
--
34.83M
+1.31%
--
--
38.24M
+6.78%
--
--
Estimates Revision
The market is revisingDownwardthe revenue expectations for Quanterix Corporation (QTRX) for FY2025, with the revenue forecasts being adjusted by -10.26%over the past three months. During the same period, the stock price has changed by-48.59%.
Revenue Estimates for FY2025
Revise Downward

-10.26%
In Past 3 Month
Stock Price
Go Down

-48.59%
In Past 3 Month
4 Analyst Rating

133.49% Upside
Wall Street analysts forecast QTRX stock price to riseover the next 12 months. According to Wall Street analysts, the average 1-year price target for QTRX is 14.50USD with a low forecast of10.00USD and a high forecast of18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy

133.49% Upside
Current: 6.210

Low
10.00
Averages
14.50
High
18.00
Scotiabank
Sung Nam
Buy
Maintains
$28 → $18
2025-03-25
Reason
Scotiabank analyst Sung Ji Nam lowered the firm's price target on Quanterix to $18 from $28 and keeps an Outperform rating on the shares. Despite the relatively stronger revenue growth performance compared to its peer group, the company's shares underperformed over the last year, the analyst tells investors. While the firm thinks the operating synergy targets are reasonable, it is less certain about the top line growth potential.
Canaccord Genuity
Kyle Mikson
Strong Buy
Maintains
$20 → $15
2025-03-18
Reason
Canaccord lowered the firm's price target on Quanterix (QTRX) to $15 from $20 and keeps a Buy rating on the shares. The firm said they continue to viewthe company as undervalued following the company's solid performance in 4Q24. That said, they recognize negative investor sentiment on its merger with Akoya Biosciences (AKYA) may negatively impact share price performance going forward.
TD Cowen
Daniel Brennan
Hold
Maintains
$14 → $16
2024-11-13
Reason
TD Cowen raised the firm's price target on Quanterix to $16 from $13.50 and keeps a Hold rating on the shares. The firm said Q3 results beat with sales and its Alzheimer's blood testing sales are nascent, though drivers are coming into place for traction in 2025 and beyond.
Scotiabank
Sung Nam
Buy
Maintains
$32 → $28
2024-08-12
Reason
TD Cowen
Daniel Brennan
Hold
Maintains
$17 → $15
2024-08-09
Reason
Goldman Sachs
Matthew Sykes
Strong Buy
Maintains
$35 → $24
2024-07-09
Reason
Canaccord Genuity
Kyle Mikson
Strong Buy
Maintains
$32 → $25
2024-04-29
Reason
Valuation Metrics
The current forward P/E ratio for Quanterix Corp(QTRX.O) is -5.18, compared to its 5-year average forward P/E of -19.16. For a more detailed relative valuation and DCF analysis to assess Quanterix Corp 's fair value, click here.
Forward PE

N/A
5Y Average PE
-19.16
Current PE
-5.18
Overvalued PE
-8.92
Undervalued PE
-29.40
Forward EV/EBITDA

N/A
5Y Average EV/EBITDA
-15.01
Current EV/EBITDA
-0.01
Overvalued EV/EBITDA
-2.22
Undervalued EV/EBITDA
-27.80
Forward PS

Undervalued
5Y Average PS
9.18
Current PS
1.78
Overvalued PS
15.21
Undervalued PS
3.16
Financials
Annual
Quarterly
FY2024Q4
YoY :
-93.09%
2.18M
Total Revenue
FY2024Q4
YoY :
+453.85%
-68.06M
Operating Profit
FY2024Q4
YoY :
+31.94%
-11.63M
Net Income after Tax
FY2024Q4
YoY :
+30.43%
-0.30
EPS - Diluted
FY2024Q4
YoY :
-51.46%
-3.98M
Free Cash Flow
FY2024Q4
YoY :
+2.50%
63.05
Gross Profit Margin - %
FY2024Q4
YoY :
+51.24%
-28.04
FCF Margin - %
FY2024Q4
YoY :
+18.40%
-33.07
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
25.5K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
831.7K
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
QTRX News & Events
Events Timeline
2025-03-24 (ET)
2025-03-24
11:06:09
Tikvah intends to vote against Quanterix's proposed merger with Akoya

2025-03-17 (ET)
2025-03-17
16:02:38
Quanterix sees FY25 revenue $140M-$146M, consensus $154.7M

2025-03-17
16:02:11
Quanterix reports Q4 EPS (30c) vs (23c) last year

2025-03-03 (ET)
2025-03-03
08:06:06
Quanterix shareholder nominates three board candidates, issues statement

2025-01-14 (ET)
2025-01-14
06:11:48
Quanterix narrows FY24 revenue view to $137.2M from $134M-$138M

2025-01-14
06:09:32
Quanterix reports preliminary Q4 revenue $34.9M, consensus $34.35M

2025-01-10 (ET)
2025-01-10
06:27:16
Quanterix to acquire Akoya Biosciences in an all-stock transaction

2024-12-17 (ET)
2024-12-17
06:00:28
Quanterix acquires EMISSION Inc.

2024-11-22 (ET)
2024-11-22
16:06:29
Quanterix receives noncompliance notification from Nasdaq

2024-11-12 (ET)
2024-11-12
15:08:18
Quanterix: Needs to restate certain prior period financial statements

2024-11-12
15:06:48
Quanterix reaffirms FY24 revenue view $134M-$138M, consensus $136.23M

2024-11-12
15:05:45
Quanterix reports preliminary Q3 revenue $35.7M, consensus $34.17M

2024-10-28 (ET)
2024-10-28
16:36:16
Lucent introduces LucentAD Complete multi-marker blood test

2024-09-30 (ET)
2024-09-30
16:01:38
Quanterix announces commercialization of p-Tau 217 test kit

2024-09-26 (ET)
2024-09-26
12:54:49
CMS publishes preliminary CLFS determinations for new codes

News
7.0
04-02Globenewswire$TOCKHOLDER ALERT: The M&A Class Action Firm Urges Shareholders of FNA, BECN, QTRX, PLYA to Take Action
5.0
04-01NewsfilterQuanterix Showcases Innovation Powered by Simoa® at AD/PD with Customer Research and New Dried Blood Spot Extraction Kit
6.0
03-25BenzingaGoldman Sachs To Rally Around 8%? Here Are 10 Top Analyst Forecasts For Tuesday
9.0
03-24NewsfilterTikvah Management Announces Intention to Vote AGAINST Quanterix's Proposed Merger with Akoya Biosciences
5.0
03-19PRnewswireSERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN
4.0
03-18Business InsiderQuanterix price target lowered to $15 from $20 at Canaccord
9.5
03-18Yahoo FinanceQuanterix Corp (QTRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges
9.5
03-17NewsfilterQuanterix Releases Financial Results for the Fourth Quarter of 2024
8.5
03-17NewsfilterKent Lake Urges Quanterix Management to Address Key Questions Regarding its Proposed Transaction with Akoya Biosciences During Today's Earnings Call
9.5
03-17NASDAQ.COMAfter-Hours Earnings Report for March 17, 2025 : BLTE, HROW, LPRO, HNRG, QTRX, DMAC, SGMO, HITI, HYPR, FGEN, RFIL, AMPS
9.5
03-17SeekingAlphaQuanterix GAAP EPS of -$0.30 misses by $0.05, revenue of $35.2M beats by $0.27M
9.5
03-17GlobenewswireAkoya Reports Fourth Quarter of 2024 and Full Year Financial Results
9.5
03-13BusinesswireQuanterix To Report Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025
9.5
03-13NewsfilterQuanterix To Report Fourth Quarter and Full Year 2024 Financial Results on March 17, 2025
9.0
03-11NewsfilterKent Lake Issues Investor Presentation Detailing Opposition to Quanterix's Proposed Merger with Akoya Biosciences
9.0
03-03BusinesswireKent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board
8.5
03-03NewsfilterQuanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition
7.0
02-24GlobenewswireBragar Eagel & Squire, P.C. Is Investigating Quanterix, e.l.f. Beauty, and Silvaco and Encourages Investors to Contact the Firm
8.5
02-18NewsfilterKent Lake Issues Letter to Quanterix Shareholders Regarding Opposition to the Company's Proposed Merger with Akoya Biosciences
7.0
02-18GlobenewswireQuanterix Corporation Announcement: If You Have Suffered Losses in Quanterix Corporation (NASDAQ: QTRX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
People Also Watch

INVA
Innoviva Inc
18.080
USD
+0.06%

CIM
Chimera Investment Corp
12.500
USD
-2.27%

NVGS
Navigator Holdings Ltd
12.230
USD
-7.49%

CNNE
Cannae Holdings Inc
17.930
USD
-5.53%

XRX
Xerox Holdings Corp
4.180
USD
-14.87%

NVEE
NV5 Global Inc
19.450
USD
-2.51%

IMKTA
Ingles Markets Inc
62.550
USD
-4.71%

FOXF
Fox Factory Holding Corp
20.910
USD
-15.92%

RC
Ready Capital Corp
4.870
USD
-4.70%

ARLO
Arlo Technologies Inc
8.510
USD
-11.63%
FAQ

What is Quanterix Corp (QTRX) stock price today?
The current price of QTRX is 6.21 USD — it hasdecreased-7.59 % in the last trading day.

What is Quanterix Corp (QTRX)'s business?

What is the price predicton of QTRX Stock?

What is Quanterix Corp (QTRX)'s revenue for the last quarter?

What is Quanterix Corp (QTRX)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Quanterix Corp (QTRX)'s fundamentals?

How many employees does Quanterix Corp (QTRX). have?
